Could a leukemia drug help fight rare lung disease? new trial aims to find out
NCT ID NCT06889168
First seen Jan 24, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study tests the long-term safety of imatinib, a drug already approved for leukemia, in women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Twenty women aged 18-64 with LAM will receive either imatinib or a placebo for 6 months. The goal is to see if imatinib is safe and tolerable over a longer period, and to measure changes in a LAM-related blood marker called VEGF-D.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.